Literature DB >> 9825274

Diagnosis and management of transient ischaemic attacks in accident and emergency.

C Libetta1, G S Venables.   

Abstract

Stroke is an important cause of morbidity and mortality. Often the first presentation of cerebrovascular disease is a TIA which will present to the A&E department. Patients who have had a TIA are at increased risk of stroke, myocardial infarction, and vascular death. The risk of stroke after a TIA is greatest in the first year (approximately 11.6%) with a risk of approximately 5.9% per year over the first five years. As the risk is highest in the first months following a TIA it is important that the patients are diagnosed accurately, investigated promptly, and referred appropriately for treatment in order that valuable time is not lost. For this reason A&E physicians have a valuable role in the initial assessment and management of the patient. It has been advocated that patients should be seen by a neurologist or physician with an interest in cerebrovascular disease within days of their symptoms and be prepared for surgery within two weeks after a TIA. While it is usually not possible to achieve this ideal, improved cooperation between A&E physicians and these neurologists, general physicians, and geriatricians should lead to the implementation of speedy efficient referral procedures which can only improve patient care. When you next see a patient with a TIA in the A&E department remember what they have to lose. Three questions relating to this article are: (1) How are TIAs subdivided and what clinical features allow this differentation? (2) What are the initial investigations that should be performed in A&E? (3) When are the risks of completed stroke greatest after a TIA? Enumerate these risks. How effective is aspirin at reducting this risks?

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9825274      PMCID: PMC1343209          DOI: 10.1136/emj.15.6.374

Source DB:  PubMed          Journal:  J Accid Emerg Med        ISSN: 1351-0622


  13 in total

1.  Cost-effective investigation of patients with suspected transient ischaemic attacks.

Authors:  G J Hankey; C P Warlow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

2.  Computed tomography in patients with transient ischaemic attacks: when is a transient ischaemic attack not a transient ischaemic attack but a stroke?

Authors:  M Dennis; J Bamford; P Sandercock; A Molyneux; C Warlow
Journal:  J Neurol       Date:  1990-07       Impact factor: 4.849

Review 3.  Transient ischaemic attacks.

Authors:  G J Hankey
Journal:  Med J Aust       Date:  1995-03-06       Impact factor: 7.738

Review 4.  Coagulation abnormalities and cerebral infarction.

Authors:  M Greaves
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-05       Impact factor: 10.154

Review 5.  Drugs and surgery in the prevention of ischemic stroke.

Authors:  H J Barnett; M Eliasziw; H E Meldrum
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

6.  Interobserver agreement for the diagnosis of transient ischemic attacks.

Authors:  C L Kraaijeveld; J van Gijn; H J Schouten; A Staal
Journal:  Stroke       Date:  1984 Jul-Aug       Impact factor: 7.914

Review 7.  Non-invasive testing for cerebrovascular disease.

Authors:  R S Lord
Journal:  Cardiovasc Surg       Date:  1996-08

8.  European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.

Authors:  H C Diener; L Cunha; C Forbes; J Sivenius; P Smets; A Lowenthal
Journal:  J Neurol Sci       Date:  1996-11       Impact factor: 3.181

9.  Prognosis of transient ischemic attacks in the Oxfordshire Community Stroke Project.

Authors:  M Dennis; J Bamford; P Sandercock; C Warlow
Journal:  Stroke       Date:  1990-06       Impact factor: 7.914

10.  Intracranial tumours that mimic transient cerebral ischaemia: lessons from a large multicentre trial. The UK TIA Study Group.

Authors: 
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-05       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.